GSK Unveils $30 Billion U.S. Investment to Boost Life Sciences and Manufacturing

GSK has announced a $30 billion investment in the U.S. over five years to enhance R&D and manufacturing, focusing on respiratory and cancer medicines. The plan includes AI and digital tech improvements, with a new factory in Pennsylvania. This move aligns with Trump's push for U.S. manufacturing.

On Wednesday, GSK revealed plans to inject $30 billion into research and development as well as supply chain infrastructure across the United States over the next five years. The announcement coincides with President Trump's visit to the UK, intended to encourage investment deals.

Central to GSK's ambitious plan is a $1.2 billion factory in Upper Merion, Pennsylvania. This facility will focus on creating medication for respiratory diseases and cancer, with construction slated for 2026. Additionally, the company seeks to enhance AI and digital technologies at its existing U.S. sites, especially in drug substance manufacturing and advanced device assembly.

The investment is expected to create tens of thousands of jobs and secure the U.S. as a leader in critical medicine development. Though the investment is substantial, GSK did not specify if included funds had previously been designated for existing projects. Nonetheless, this strategy supports Trump's emphasis on domestic manufacturing, even as the industry looks to avoid trade tensions historically faced by other sectors.

(With inputs from agencies.)